What question did this study set out to answer?

Characterize the binding mechanism, selectivity, and antitumor efficacy of the novel kinase inhibitor SB-590885 in cancer cells driven by oncogenic BRAF mutations.

December 1, 2006Cancer ResearchOpen Access

Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885

View Full Paper

Ask AI

Bookmark

Authors

AKAlastair J. KingCharles River Laboratories (Netherlands)DPDenis R. PatrickMerck & Co., Inc., Rahway, NJ, USA (United States)RBRoberta S. BatorskyNew England Biolabs (United States)

Discussion

Member takes

Implication

Preclinical study reveals selective growth inhibition in oncogenic BRAF-mutant cancer cells by SB-590885, highlighting a genetic therapeutic window for targeted kinase therapy.

Key Points

Characterize the binding mechanism, selectivity, and antitumor efficacy of the novel kinase inhibitor SB-590885 in cancer cells driven by oncogenic BRAF mutations.
Performed crystallographic structural analysis of SB-590885 complexed with the oncogenic B-Raf kinase domain.
Assessed biochemical kinase inhibition profiles, comparing potency between B-Raf and c-Raf isoforms.
Evaluated mitogen-activated protein kinase signaling, proliferation, transformation, and tumorigenicity in oncogenic B-Raf cancer cell lines, non-mutant cancer cells, and normal cells.
SB-590885 selectively inhibited Raf kinases with higher potency against B-Raf than c-Raf, stabilizing the active kinase conformation through a distinct structural mechanism from BAY43-9006.
Cells harboring oncogenic B-Raf demonstrated selective suppression of mitogen-activated protein kinase activation, cell proliferation, transformation, and tumorigenicity.
Non-mutant cancer cell lines and normal cells showed variable sensitivity or resistance, establishing a positive correlation between oncogenic BRAF expression and inhibitor response.

Cite This Study

King et al. (2006) studied this question.

synapsesocial.com/papers/6a72645a5671bbf00bc310a2 https://doi.org/10.1158/0008-5472.can-06-2554

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study reveals selective growth inhibition in oncogenic BRAF-mutant cancer cells by SB-590885, highlighting a genetic therapeutic window for targeted kinase therapy.

Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885

Discussion

Member takes

Implication

Key Points

Cite This Study

Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider